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Tendinopathy is a major problem in 
medicine and sports traumatology1. It is 
due, inter alia, to mechanical overload1. 
Painful and disabling, it frequently leads to 
athletes being unable to perform and may 
sometimes even impair their quality of life. 
It remains a challenge for the medical world, 
to the extent that its frequent resistance to 
conventional treatments rarely gives the 
patient a favourable outcome following 
therapeutic management1.
The development of platelet-rich plasma 
(PRP) offers new hope when therapeutic 
treatments such as non-steroidal anti-
inflammatory drugs, corticosteroid 
injections, eccentric rehabilitation, shock 
waves etc. have been unsuccessful2. 
Current knowledge does not, at this time, 
consider PRP a primary treatment. This 
new treatment has drawn the attention 
of clinicians, especially those active in the 
sporting environment. Furthermore, in 
January 2011, it was removed from the list of 
doping substances (www.wada-ama.org)2.
PLATELET-RICH PLASMA
The platelets perform various functions 
during the process of haemostasis, they 
aggregate at the lesion edges to form a 
procoagulant surface area and are also 
involved in the inflammatory process 
through the release of various factors of 
vascular permeability, the increase in 
neutrophil chemotaxis and prostaglandin 
synthesis. Finally, they modulate the 
immune defence system. The ‘restorative’ 
properties of platelets are used because 
they support the healing process of various 
tissues (bone, skin, muscle and tendon)3.
Their cytoplasm contains granulations 
that are visible through an electron 
microscope, including alpha granules 
containing various adhesion proteins 
(particularly the von Willebrand 
factor), coagulation factors, cytokines, 
metalloproteinases and various growth 
factors4. They exert a synergistic action 
with other signalling molecules and/or 
other growth factors and are involved in the 
healing process of tendons, notably4:
• Platelet-derived growth factor (PDGF): 
stimulates the production of other 
growth factors and proteins during the 
inflammatory phase and is involved in 
tissue remodelling.
• Transforming growth factor-β 
(TGF-β): stimulates migration and cell 
proliferation, collagen synthesis and 
regulates proteinases.
• Fibroblast growth factor (FGF): 
stimulates angiogenesis and during the 
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• Vascular endothelial growth factor 
(VEGF): stimulates angiogenesis during 
the proliferative and remodelling 
phases.
• Hepatocyte growth factor (HGF): 
stimulates angiogenesis, cell 
proliferation and migration. It also has 
an anti-inflammatory and anti-fibrotic 
action.
• Insulin-like growth factor 1 (IGF-
1): leads, during the inflammatory 
phase, to fibroblast proliferation and 
migration. During the remodelling 
phase it promotes the local production 
of collagen and various structures of the 
extracellular matrix.
The ratio between the various factors 
could influence the dynamic balance 
between the cells, as well as angiogenesis 
and the formation of the extracellular 
matrix.
PRP is obtained by centrifugation of 
autologous blood to obtain a platelet 
concentration greater than that of the 
autologous blood, which varies according 
to the production method5,6. PRP can be 
activated prior to its injection through 
the addition of thrombin or calcium 
chloride, the alternative being in-situ 
activation by collagen7. PRP also contains a 
variable amount of lymphocytes, which is 
suggested to have a detrimental effect on 
wound healing through the release of pro-
inflammatory factors potentially responsible 
for degradation of the extracellular matrix7. 
The lack of red blood cells is also necessary 
because their lysis would result in a release of 
free radicals that can be damaging to tissue 
structures7. Currently, there is no formal 
consensus regarding the production method 
or the biological composition of PRP7. Based 
on pre-clinical studies, we can nonetheless 
reasonably assume that the ideal PRP should 
not contain any white or red cells. However, 
this assertion is not clinically proven. 
PRECLINICAL STUDIES
Some laboratory studies (in-vitro and/or 
on animal) emphasise the acceleration of the 
tendon healing process after the injection of 
PRP, each growth factor exerting a specific 
action during healing8. PRP would cause the 
proliferation, migration and differentiation 
of cells derived from circulation, improving 
the initial phase of tendon healing8-13. 
Cellular activation can be explained by the 
local production of growth factors. This 
anabolic process initiates type I collagen 
synthesis9. PRP stimulates the proliferation 
of human tenocytes and collagen production 
but also slightly increases the expression of 
metalloproteinases involved in remodelling 
of the extracellular matrix14. 
Figure 1: Animal experimental procedures. Surgical procedure: the Achilles and plantaris tendons were dissected. The plantaris tendon was 
removed. The Achilles tendon was transected and a 5-mm defect was made. The fascia and the skin were each surgically closed before 
injection of PRP.
Figure 2: The traction-compression testing machine (106.2 kN, TesT GmbH, Dusseldorf, Germany) and an original clamping device type 
'cryo-jaw' to perform the mechanical testing of the tendon.
Figure 3: Once the tendon had healed, the muscle-tendon-bone unit was fastened in the clamping device by freezing the muscular segment 





However, according to an animal model 
(progenitor cells of rabbit tendons), PRP 
was not sufficiently active to slow down 
the degenerative process of late stage 
tendinopathy, characterised by lipid 
deposits, calcification and an accumulation 
of proteoglycans15.
An injection of PRP improves tendon 
repair in rats, where the Achilles tendon had 
been previously sectioned. Within the PRP 
group, better maturation of the tendinous 
callus and an increase in its resistance to 
breakage were assessed9. PRP is suggested 
to improve the organisation of collagen 
fibres; stimulating neovascularisation and 
accelerating the healing process (which 
was also of better quality), confirming 
other results in the same experimental 
conditions9,16,17. After injecting PRP into 
rabbits, the mechanical properties (tensile 
strength and response to mechanical 
stress) of the injured patellar tendon 
improves8. VEGF, a growth factor released 
by platelets, stimulates tendon healing and 
regulates the expression of other growth 
factors, including TGF-β18. Horses with 
injured tendons that are injected with PRP 
experience, after a few weeks, an increase in 
DNA, glycosaminoglycans and, in particular, 
collagen synthesis19. These tendons present 
better elasticity and a higher resistance to 
breakage19. Biochemical and histological 
analyses show a higher metabolic activity 
and more advanced tissue repair after 
injecting PRP.
Similar results have been reported in an 
animal model with patellar tendinitis and 
chemical calcaneal tendinitis (injection 
of collagenase)20 – an ultrasound-guided 
intra-tendon injection of PRP promoted the 
healing of these chemical tendinopathies8.
CLINICAL STUDIES
Although the effectiveness of PRP on 
tendon healing in-vitro or in animals 
seems to be confirmed, clinical studies are 
currently still controversial. In addition, 
there are a growing number of randomised 
and controlled studies reviewing PRP for 
treating tendinopathy. 
Epicondylitis
The very first study specifically assessing 
the effect of PRP when treating tendinopathy 
was reported on epicondylitis21. The two 
small non-randomised groups (a single 
injection of PRP (n=15) vs. local anaesthetic 
Images: Activated pure PRP (without 
leukocytes) in the syringe and injections 
of PRP in various tendons (patellar and 




(n=5)) received eccentric rehabilitation using 
elastics after the injection. The pain receded 
more significantly with the PRP group at 8 
weeks, 6 months and 24 months. After 2 
years, 94% of patients returned to sport and/
or previous professional activities; however, 
longitudinal observation of patient controls 
did not exceed 8 weeks and was not able to 
be compared to the PRP group further.
A first systematic review (literature until 
October 2013 included) concluded that there 
is evidence against the efficacy of PRP in 
the treatment of epicondylitis22. Of the six 
studies included, only four were considered 
high-level and among those, three showed 
that injections of PRP were not effective in 
treating epicondylitis, with one showing 
a real clinical efficacy. However, in a meta-
analysis (articles until March 2014), seven 
randomised controlled trials (RCT) were 
selected (including 6 selected in the previous 
systematic review)23. When analysing the 
results of the different studies, a reduction 
in pain and algo-functional scores were 
observed within the patients in the PRP 
group compared to the control groups. It 
takes at least 3 to 6 months before this 
significant improvement could be observed. 
Another systematic review (articles until 
April 2014) also concluded that the use 
of PRP for treating epicondylitis is very 
promising in the short- to medium-term (up 
to 6 months)24. In conclusion, even though 
some evidence exists to support the use of 
PRP in chronic epicondylitis, the current 
literature does not provide strong evidence 
for its use in first-line treatment.
Tendinopathies of the rotator cuff
In the same meta-analysis (articles until 
March 2014), two RCTs compared the effect of 
PRP on tendinopathy of the rotator cuff with 
a control group23. Among them, one study (6 
months) highlighted the effectiveness of two 
PRP injections compared to two injections 
with a simple dry needle under ultrasound 
guidance25. After the first injection, the two 
groups developed comparably, after the 
second injection of PRP, clinical improve-
ment (pain and shoulder mobility) occurred, 
compared to the control group. The results 
of the meta-analysis (up to 1 year) showed 
favourable development compared with the 
control groups, but was less evident than 
for epicondylitis. This was confirmed in a 
final systematic review (articles up to April 
2014), concluding that there was a lack of 
conclusive evidence to support the use of PRP 
in this indication24. 
Patellar tendinopathy
A systematic review of 13 studies on 
PRP (articles up to July 2014)  included 
two RCTs on the effect of PRP on patellar 
tendinopathy26. Two injections of PRP were 
compared with three shockwave sessions27. 
The PRP group showed better development 
than the shockwave group at 6 and 12 
months for pain and algo-functional 
scores, showing that injections of PRP are 
more effective in the medium-term than 
the shockwaves in this indication. The 
authors of the systematic review therefore 
concluded that PRP would seem more 
useful for treating stubborn tendinopathy 
than other conservative treatments and 
can be regarded as a second-line therapy26. 
However, evidence from high-level studies 
is still needed. Three controlled studies 
(including 2 RCTs) analysed in another 
systematic review (articles up to February 
2014) showed that for patellar tendinopathy, 
even if PRP is a safe and promising technique, 
its superiority over other conservative 
treatments is unproven28. 
Calcaneal tendinopathy
Calcaneal or Achilles tendinopathy is 
very common among athletes, especially 
long distance runners1. A systematic 
review of 12 studies (articles up to July 
2014), of which only one was an RCT (which 
was also included in a meta-analysis 
(articles up to March 2014) and in another 
systematic review (articles up to April 
2014)) assessed PRP as a treatment for 
Achilles tendinopathy23,24,26. However, it did 
not show the efficacy of PRP (clinical and 
ultrasound) compared to an injection of 
body fluid followed by a 3 months eccentric 
rehabilitation, with a 1 year follow-up29,30. 
This study has some limitations, including 
the lack of eccentric rehabilitation (which 
may be effective only before the injection) in 
all patients before inclusion31. Nevertheless, 
until now, there remains an absence of 
evidence for the use of PRP in calcaneal 
insertional tendinopathy.
Plantar fasciopathy
Also known by the name plantar fasciitis, 
it is an irritation of the fascia sheathing the 
tendons responsible for maintaining the 
plantar arch. It is not a tendon itself, but the 
symptoms and accompanying treatment 
are similar to those found in tendinopathy, 
which is why it has been included in this 
review.
A systematic review (articles up to June 
2014) analysed eight studies including three 
RCTs32. Although current observations and 
conclusions are promising, they remain 
limited with regard to the change in pain 
and high-functional scores of the PRP group 
compared with the control group, justifying 
the continuation of high-level studies in this 
pathology.
DISCUSSION
Tendinopathy is a very common 
condition in sportspeople. Its treatment 
remains a challenge because many athletes 
disregard classical conservative treatments 
and the condition becomes chronic. For 
this reason, new treatments have been 
developed, including PRP injections. 
However, until now, despite the in-vitro 
efficacy of PRP on tissue regeneration8, there 
is an absence of strong evidence to support 
its use on tendinopathy22,24,26,28,32. 
Recommendations for daily practice
• PRP should be injected into the lesion, possibly under ultrasound 
guidance. After the injection, submaximal and gradual eccentric 
rehabilitation improves the quality of tendon healing.
• Based on the current literature, even though some evidence exists to 
support the use of PRP injections to treat epicondylitis and patellar 
tendinopathies, this treatment is not recommended as a first-line 
treatment of tendinopathies.
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PRP therapy has been used for several 
years in various surgical specialties, 
with favourable clinical results regularly 
suggested3. Through the release of platelet 
growth factors, PRP would likely be an 
attractive alternative therapy for chronic 
tendinopathy   its easy preparation and low 
invasiveness are additional advantages3. 
Studies on the use of PRP have not reported 
any serious side effects33, nevertheless, it 
should be ensured that any side effects are 
actually published. Studies are difficult 
to compare because the methods of 
preparation, the qualitative characteristics 
of PRP (volume, platelet concentration, 
presence of leukocytes and erythrocytes), 
the injection technique and the post-
injection rehabilitative protocol are not 
clearly defined. 
After the injection, submaximal and 
gradual eccentric rehabilitation improves 
the healing quality of the tendon34. Indeed, 
PRP initiates a healing process secondarily 
developed by the vector of eccentric forces35.
PRP exhibits very variable platelet, 
erythrocyte and leukocyte concentrations 
depending on its preparation protocol5,6. 
The optimum concentration of platelets for 
therapeutic treatment of tendon injuries 
has not yet been validated. The pre-clinical 
literature suggests, however, the following7:
• A platelet concentration of less than 106 
platelets/μL (i.e. 3 to 4x blood platelet 
concentration) might be optimal, while 
a concentration higher than 1.2 x 106 
would have a paradoxical effect of 
inhibiting collagen synthesis.
• There is an ongoing debate on the 
effect of leukocytes. Some studies do 
not advocate the inclusion of white 
blood cells because they might slow 
the healing process due to the early 
induction of a larger local inflammatory 
reaction and the presence of pro-
inflammatory factors (cytokines 
and metalloproteinases) capable of 
degrading the extracellular matrix. 
PRP containing leukocytes would also 
reduce collagen synthesis. In addition to 
this it was shown that the anti-bacterial 
effect of PRP against Staphylococcus 
aureus, Staphylococcus epidermidis, 
Propionibacterium acnes and 
methicillin-resistant Staphylococcus 
aureus (MRSA) was not related to the 
presence of white blood cells.
• No red blood cells; once lysed they 
release various free radicals similar to 
those of leukocytes that could actually 
damage the surrounding tissue.
Ideally, one should be able to inject 
a reproducible PRP (same platelet 
concentration) into all patients. Currently, 
unlike all other PRP preparation techniques, 
only platelet collection via an apheresis 
machine can easily achieve this36,37.
Even if the product spreads from the 
injection site, it should be performed 
under ultrasound guidance while 
respecting aseptic precautions. Local 
anaesthesia is not recommended so 
as not to compromise the therapeutic 
potential of PRP, but this recommendation 
is not supported by strong evidence7. A 
preliminary activation (e.g. CaCl2) would 
allow for platelet degranulation and a 
more rapid release of growth factors, but 
its suggested effect is variable38. During 
the post-injection hyperalgic period, only 
painkillers and cryotherapy are allowed. 
Non-steroidal anti-inflammatory drugs 
must be avoided, at least from 10 days 
before to 21 days after the injection, as 
they may prevent PRP from working7. 
Thereafter, sub-maximal eccentric 
rehabilitation of gradually increasing 
intensity combined with stretching will 
‘guide’ tendon healing34. During the 
gradual return to sport any technopathy 
will be corrected and the tendon 
would be somewhat ‘protected’ using 
‘functional’ orthotics (e.g. patellar band) 
or strapping7. The results at 3 months are 
used to evaluate the effect of the injection 
of PRP and discuss the indication of a 
second injection of PRP in case of a partial 
improvement of tendon symptoms. 
Indeed, two successive injections of PRP 
(15 days apart) do not seem to be justified37. 
Surgery should be discussed if there is no 
improvement.
CONCLUSION
Experimentally, through the local release 
of various growth factors, PRP stimulates 
tendon healing. This therapy could optimise 
the healing of pathological human tendons. 
However, based on the current literature, 
PRP injections are not recommended as 
first-line treatment for tendinopathies. 
PRP should be analysed to see whether it 
improves tendon healing in both humans 
and animals through further RCTs. Indeed, 
the effectiveness of PRP in clinical practice 
remains controversial despite interesting 
results for patellar tendinopathy and 
epicondylitis.
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Recommendations for future research
•  A standardisation of the quality of the PRP is mandatory. The use of 
an identical platelet concentration with the same technique among 
all patients could help to improve this therapy. Moreover, a general 
agreement on the presence or not of leukocytes is required, even if pre-
clinical studies advise against their presence.
•  Randomised controlled studies are still needed to give strong evidence 
for the use of PRP injections in chronic tendinopathies.
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